Figure 1.

Economics of anti-VEGF biosimilars. (a). Price of anti-VEGF injection in India (US dollars; $); (b). Graph showing ewillingness to payf price of ranibizumab biosimilar (Razumab) at which the respondents would switch from Avastin. (c). Graph showing similar proportion of respondents in 2018 and 2020 who are of the opinion that the current price of the ranibizumab biosimilar warranted a switch from Avastin. (d). Graph showing that a majority of respondents believe that biosimilars have made anti-VEGF treatment more affordable